UP!

ALOG $83.95   View long term graphs

Analogic Corporation
Type
Public
Traded as NASDAQ: ALOG
S&P 600 Component
Industry Medical Imaging
Ultrasound
Security
Founded Wakefield, Massachusetts (1967)
Headquarters Peabody, Massachusetts
Key people
Fred Parks,
President & CEO
Bernard Bailey,
Chairman of the Board
Products Medical & Security Imaging Systems and Subsystems; Ultrasound Systems & Transducers
Revenue $517.5 million USD (Fiscal 2014)
Number of employees
1,500
Website www.analogic.com

Analogic is an American multinational corporation. Analogic Corporation currently employs 1,500 employees worldwide with approximately 900 working at the main facility and headquarters in Peabody, Massachusetts.

When Bernard M. Gordon, chairman emeritus, founded Analogic in 1967, his inventions had already made their mark in history. That tradition of inventiveness has continued ever since. Today, Analogic has a long list of innovations and achievements resulting from more than 40 years of developing leading-edge technologies. Analogic is an innovator in computed tomography signal processing and a recognized leader in diagnostic medical imaging and security imaging. With over 190 U.S. patents issued, with corresponding foreign patents, and many more pending, Analogic's history speaks for itself.

Analogic provides health care and security technology solutions to advance the practice of medicine and save lives. Analogic is recognized around the world for advanced imaging systems and technology that enable computed tomography (CT), ultrasound, digital mammography, and magnetic resonance imaging (MRI), as well as automated threat detection for aviation security. The company's CT, MRI, digital mammography, and ultrasound transducer products are sold to original equipment manufacturers (OEMs), providing state-of-the-art capability and enabling them to enter new markets and expand their existing market presence. Its BK Medical branded ultrasound systems, used in procedure-driven markets such as urology, guided surgery, and anesthesia, are sold to clinical end users through Analogic's direct sales force.


News

Analogic Corporation (healthcare)

Q reports

Period Date Adjusted Actuals EPS GAAP EPS
Q4 2018 2018-09-17 Future report Set alerts
Q3 2018 2018-06-04 1.08 0.56
Q2 2018 2018-03-05 1.27 0.52
Q1 2018 2017-12-06 0.75 0.45
Q4 2017 2017-09-19 0.42 -1.98
Q3 2017 2017-06-06 0.79 -4.78
Q2 2017 2017-03-06 0.99 0.59
Q1 2017 2016-12-06 0.43 0.20
Q4 2016 2016-09-21 1.02 0.70
Q3 2016 2016-06-01 0.80 0.40

Ratings

2016-06-02 Reiterated Rating Brean Capital Buy
2016-03-24 Initiated Coverage Sidoti Neutral $81.00
2016-03-03 Reiterated Rating Brean Capital Buy $90.00
2015-12-09 Reiterated Rating Brean Capital Buy $110.00
2015-11-23 Lower Price Target Benchmark Co. $89.00
2015-10-09 Reiterated Rating Brean Capital Buy
2015-09-15 Reiterated Rating Brean Capital Buy $110.00
2015-06-04 Upgrade Brean Capital Buy $110.00
2015-03-24 Upgrade Wells Fargo & Co. Market Perform to Outperform
2015-03-24 Upgrade Brean Capital Hold to Buy $110.00
2015-03-24 Upgrade Wells Fargo Market Perform to Outperform
2015-03-11 Reiterated Rating Brean Capital Hold
2015-02-11 Reiterated Rating Brean Capital Hold
2014-09-16 Downgrade Brean Capital Buy to Hold $95.00
2014-06-06 Reiterated Rating Benchmark Co. Buy $105.00 to $91.00
2014-03-14 Upgrade Sidoti Neutral to Buy
2014-03-07 Downgrade CJS Securities Outperform to Market Perform $97.00 to $90.00
2013-12-16 Initiated Coverage Brean Capital Buy $100.00
2013-10-21 Boost Price Target Benchmark Co. Buy $89.00 to $105.00
2012-09-14 Upgrade Needham Hold to Buy $85
2012-09-14 Reiterated The Benchmark Company Buy $82 to $90
2012-06-07 Downgrade Needham Buy to Hold $66
2012-03-29 Reiterated The Benchmark Company Buy $65 to $82
2012-03-07 Reiterated Needham Buy $62 to $66
2011-12-09 Reiterated The Benchmark Company Buy $60 to $65
2010-05-25 Upgrade The Benchmark Company Hold to Buy $40 to $50
2010-05-25 Upgrade Benchmark Hold to Buy $40 to $50
2010-03-26 Initiated Benchmark Hold
2010-03-10 Upgrade Needham Hold to Buy $50
2010-01-14 Upgrade Dougherty & Company Sell to Neutral $30 to $40
2009-12-10 Downgrade Needham Buy to Hold
2009-09-18 Downgrade Dougherty & Company Neutral to Sell $30
2009-08-05 Downgrade Stifel Nicolaus Buy to Hold
2009-06-18 Initiated Dougherty & Company Neutral $40
2009-01-29 Reiterated Stifel Nicolaus Buy $65 to $60
2008-12-10 Reiterated Stifel Nicolaus Buy $75 to $65
2008-12-10 Reiterated Stanford Research Hold $44 to $34
2008-12-10 Reiterated Needham Buy $72 to $45
2008-11-03 Downgrade Stanford Research Buy to Hold $44
2016-06-02 Reiterated Rating Brean Capital Buy
2016-03-24 Initiated Coverage Sidoti Neutral $81.00
2016-03-03 Reiterated Rating Brean Capital Buy $90.00
2015-12-09 Reiterated Rating Brean Capital Buy $110.00
2015-11-23 Lower Price Target Benchmark Co. $89.00

There is presents forecasts of rating agencies and recommendations for investors about this ticker

Major Shareholders

Name Relationship Total Shares Holding stocks
Green James W President/CEO/Director 0.15%  (18790) ALOG / HBIO /
Peechatka Farley Sr VP-GM & Glbl Ultrasound Bus 0.15%  (18635) ALOG /
Fry John J President/CEO/Director 0.15%  (18201) ALOG /
VOBORIL EDWARD F 0.13%  (15631) ALOG /
PARKS FRED B 0.09%  (11742) ALOG /
Faltas Mervat Sr VP and GM-OEM Medical Group 0.08%  (9529) ALOG /
BAILEY BERNARD C 0.06%  (7282) ALOG /
MELIA KEVIN C 0.06%  (7242) ALOG / ANET / GB / RSYS /
BLACK JEFFREY P 0.05%  (6647) ALOG /
Vandebroek Sophie V. 0.05%  (6185) ALOG / IDXX /
ODLAND STEPHEN A 0.04%  (4576) ALOG / GIS /
Levitz Michael L Sr. VP-CFO & Treasurer 0.03%  (4331) ALOG / PODD /
Chandra Shalabh See Remarks 0.03%  (3317) ALOG /
Ryan James Patrick SVP, Global Operations 0.02%  (2354) ALOG /
Frost Mark T SVP, CFO & Treasurer 0.01%  (1442) ALOG / ANGO /
Bourque Michael J. See Remarks 0.01%  (990) ALOG /

Comments